| 5.11 0.49 (10.61%) | 03-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.53 | 1-year : | 7.29 |
| Resists | First : | 5.59 | Second : | 6.25 |
| Pivot price | 5.11  |
|||
| Supports | First : | 4.54 | Second : | 3.78 |
| MAs | MA(5) : | 4.81 |
MA(20) : | 5.24 |
| MA(100) : | 6.14 |
MA(250) : | 6.29 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.1 |
D(3) : | 11.3 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 11.4 | Low : | 1.73 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SGMT ] has closed above bottom band by 49.8%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.13 - 5.16 | 5.16 - 5.18 |
| Low: | 4.51 - 4.54 | 4.54 - 4.58 |
| Close: | 5.05 - 5.11 | 5.11 - 5.16 |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Wed, 25 Mar 2026
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Yahoo Finance UK
Sun, 22 Mar 2026
If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan
Wed, 11 Mar 2026
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Wed, 04 Mar 2026
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Wed, 25 Feb 2026
Biotech Sagimet lines up three March investor conferences - Stock Titan
Wed, 25 Feb 2026
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 46.4 (%) |
| Shares Short | 3,890 (K) |
| Shares Short P.Month | 3,200 (K) |
| EPS | -1.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.6 % |
| Return on Equity (ttm) | -39.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -2.88 |
| PEG Ratio | 0 |
| Price to Book value | 1.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|